This site is intended for healthcare professionals only    

PCRA Logo

Stepping down ICS therapy in COPD

Posted on: 21 Jun 2018
 

PCRS has produced a guide for the evaluation of inhaled corticosteroid (ICS) therapy in COPD and guidance on appropriate ICS withdrawal.

Long-acting bronchodilators are first-line treatment for symptomatic patients with COPD at low risk of exacerbation. The addition of ICS is recommended for patients with concomitant asthma and COPD. Also, it is advocated in COPD patients with severe-to-very-severe airflow limitation and/or frequent exacerbation (two or more per year) not adequately controlled by long-acting bronchodilators. Likewise, the addition of ICS is proposed for patients who experience one or more hospitalisations for exacerbation.

In most industrialised countries, approximately 40% of patients diagnosed with COPD are candidates for ICS. This is according to criteria set by the Global Initiative for COPD. However, prescribing rates can exceed 80%. This means not only that many patients are being exposed to the risks associated with ICS, but that the cost of their care is unnecessarily high.

Therefore, it is important to know whether and how ICS treatment can be safely withdrawn.

Stepping down ICS therapy in COPD



Other articles




Media partners


Sponsors

GSK Logo

Clinical and Commissioning
Platform sponsor

Boehringer Logo

Community Pharmacy Platform sponsor

Orion Pharma Logo

Commissioning Platform sponsor

The Primary Care Respiratory Academy has been developed and is produced by Cogora, the publisher of Pulse, Nursing in Practice, Healthcare Leader and Management in Practice and The Pharmacist working in partnership with PCRS. All educational content for the website and roadshows has been initiated and produced by PCRS/Cogora.